Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises
Natesh Singh, Bruno O. Villoutreix
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 2537-2548
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 136
Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery
Zhonglei Wang, Liyan Yang, Xian‐En Zhao
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 4684-4701
Open Access | Times Cited: 36
Identification of SARS‐CoV‐2 Papain‐like Protease (PLpro) Inhibitors Using Combined Computational Approach**
Milan Senćanski, Vladimir Perović, Jelena Мilićević, et al.
ChemistryOpen (2022) Vol. 11, Iss. 2
Open Access | Times Cited: 17
COVID-19 infection and neurodegeneration: Computational evidence for interactions between the SARS-CoV-2 spike protein and monoamine oxidase enzymes
Lucija Hok, Hrvoje Rimac, Janez Mavri, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 1254-1263
Open Access | Times Cited: 15
Computational Approaches in the Discovery and Development of Therapeutic and Prophylactic Agents for Viral Diseases
Anand Gaurav, Neetu Agrawal, Mayasah Al‐Nema, et al.
Current Topics in Medicinal Chemistry (2022) Vol. 22, Iss. 26, pp. 2190-2206
Closed Access | Times Cited: 15
Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors
Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonkululeko Avril Mbatha, et al.
(2023)
Open Access | Times Cited: 8
Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease
Michael G. Sugiyama, Haotian Cui, Dar’ya S. Redka, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 19
Combination Therapy of Ledipasvir and Itraconazole in the Treatment of COVID-19 Patients Coinfected with Black Fungus: An In Silico Statement
Supriyo Saha, Gyu Seong Yeom, Satish Balasaheb Nimse, et al.
BioMed Research International (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 11
In Silico Therapeutic Study: The Next Frontier in the Fight against SARS-CoV-2 and Its Variants
Calvin R. Wei, Zarrin Basharat, Godwin C. Lang’at
Drugs and Drug Candidates (2024) Vol. 3, Iss. 1, pp. 54-69
Open Access | Times Cited: 1
Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants
Sankalp Jain, Daniel C. Talley, Bolormaa Baljinnyam, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 5, pp. 1675-1688
Open Access | Times Cited: 11
Development of a potent recombinant scFv antibody against the SARS-CoV-2 by in-depth bioinformatics study: Paving the way for vaccine/diagnostics development
Fatemeh Yaghoobizadeh, Mohammad Roayaei Ardakani‬, Mohammad Mehdi Ranjbar, et al.
Computers in Biology and Medicine (2024) Vol. 170, pp. 108091-108091
Closed Access
Integrative in silico evaluation of the antiviral potential of terpenoids and its metal complexes derived from Homalomena aromatica based on main protease of SARS-CoV-2
Ashis Kumar Goswami, Mourad A. M. Aboul‐Soud, Neelutpal Gogoi, et al.
Open Chemistry (2024) Vol. 22, Iss. 1
Open Access
Expression, purification, and study on the efficiency of a new potent recombinant scFv antibody against the SARS-CoV-2 spike RBD in E. coli BL21
Fatemeh Yaghoobizadeh, Mohammad Roayaei Ardakani‬, Mohammad Mehdi Ranjbar, et al.
Protein Expression and Purification (2022) Vol. 203, pp. 106210-106210
Open Access | Times Cited: 3
COVID-19 Therapies: Protease Inhibitions and Novel Degrader Strategies
Michèle Reboud‐Ravaux, Chahrazade El Amri
Frontiers in Drug Discovery (2022) Vol. 2
Open Access | Times Cited: 3
Development of complemented comprehensive networks for rapid screening of repurposable drugs applicable to new emerging disease outbreaks
Yonghyun Nam, Anastasia Lucas, Jae‐Seung Yun, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications
Zhihan Wang, Kai Guo, Pan Gao, et al.
Precision Clinical Medicine (2021) Vol. 4, Iss. 4, pp. 215-230
Open Access | Times Cited: 3
Peptides, lipopeptides, and severe acute respiratory syndrome coronavirus-2
Furqan Shafqat, Shafeeq Ur Rehman, Muhammad Shan, et al.
Elsevier eBooks (2022), pp. 381-422
Closed Access | Times Cited: 1
Multiscale interactome analysis coupled with off‑target drug predictions reveals drug repurposing candidates for human coronavirus disease
Michael G. Sugiyama, Haotian Cui, Dar’ya S. Redka, et al.
(2023)
Open Access
Multiscale interactome analysis coupled with off‑target drug predictions reveals drug repurposing candidates for human coronavirus disease
Michael G. Sugiyama, Haotian Cui, Dar’ya S. Redka, et al.
(2023)
Open Access
Computational screening of phytochemicals for anti-viral drug discovery
Andrew G. Mtewa, Jonathan T. Bvunzawabaya
Elsevier eBooks (2023), pp. 245-256
Closed Access
Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease
Michael G. Sugiyama, Haotian Cui, Dar’ya S. Redka, et al.
(2023)
Open Access
Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease
Michael G. Sugiyama, Haotian Cui, Dar’ya S. Redka, et al.
(2023)
Open Access
Comparative docking and molecular dynamics studies of molnupiravir (EIDD-2801): implications for novel mechanisms of action on influenza and SARS-CoV-2 protein targets
Erman Salih İstifli, Nurullah Okumuş, Cengiz Sarıkürkçü, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 15, pp. 8202-8214
Closed Access
Effect of new derivatives of 6,7-dimethoxyquinazoline-4(3H)-one with amino acid residues and dipeptide fragments on the activity of the main protease (Mpro) and papain-like protease (PLpro) of SARS-CoV-2
D. I. Pozdnyakov, A. Chiriapkin, И. П. Кодониди
JOURNAL of SIBERIAN MEDICAL SCIENCES (2023) Vol. 7, Iss. 3, pp. 27-36
Open Access
Identification of SARS-CoV-2 Papain-like protease (PLpro) inhibitors using combined computational approach
Milan Senćanski, Vladimir Perović, Jelena Мilićević, et al.
(2021)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top